112 related articles for article (PubMed ID: 16038734)
41. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
[TBL] [Abstract][Full Text] [Related]
42. e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia.
Roti G; La Starza R; Gorello P; Gottardi E; Crescenzi B; Martelli MF; Mecucci C
Haematologica; 2005 Aug; 90(8):1139-41. PubMed ID: 16079118
[TBL] [Abstract][Full Text] [Related]
43. Comparative quantitative analysis of BCR-ABL transcripts with the T315I mutant clone by polymerase chain reaction (PCR)-Invader method.
Tadokoro K; Ishikawa M; Suzuki M; Saito T; Suzuki Y; Yamaguchi T; Yagasaki F
Transl Res; 2011 Sep; 158(3):169-79. PubMed ID: 21867983
[TBL] [Abstract][Full Text] [Related]
44. A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.
Li X; Yang J; Chen X; Liu J; Li H; Zheng J; He Y; Chen Z; Huang S
Cancer Genet Cytogenet; 2007 Jul; 176(2):166-8. PubMed ID: 17656262
[TBL] [Abstract][Full Text] [Related]
45. Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia.
Menif S; Zarrouki S; Jeddi R; ben Alaya N; Ali ZB; Ben Abid H; Hdeiji S; Elloumi M; Khlif A; Meddeb B; Dellagi K
Pathol Biol (Paris); 2009 Jul; 57(5):388-91. PubMed ID: 18387753
[TBL] [Abstract][Full Text] [Related]
46. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
Qin YZ; Jiang B; Jiang Q; Zhang Y; Jiang H; Li JL; Zhu HH; Li LD; Liu YR; Chen SS; Huang XJ
Acta Haematol; 2008; 120(3):146-9. PubMed ID: 19039205
[TBL] [Abstract][Full Text] [Related]
47. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
48. First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.
Andrikovics H; Nahajevszky S; Szilvási A; Bors A; Adám E; Kozma A; Kajtár B; Barta A; Poros A; Tordai A
Hematol Oncol; 2007 Sep; 25(3):143-7. PubMed ID: 17530620
[TBL] [Abstract][Full Text] [Related]
49. Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment.
Galimberti S; Cervetti G; Guerrini F; Testi R; Pacini S; Fazzi R; Simi P; Petrini M
Cancer Genet Cytogenet; 2005 Oct; 162(1):57-62. PubMed ID: 16157201
[TBL] [Abstract][Full Text] [Related]
50. Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript.
Tchirkov A; Couderc JL; Périssel B; Goumy C; Regnier A; Uhrhammer N; Verrelle P; Berger M
Leukemia; 2006 Jan; 20(1):167-8. PubMed ID: 16270035
[No Abstract] [Full Text] [Related]
51. Second case of CML with aberrant BCR-ABL fusion transcript (e8/a2) with insertion of an inverted ABL intron 1b sequence.
Sugimoto T; Ijima K; Hisatomi H; Murayama T; Mizuno I; Hato A; Imoto S; Nishimura R; Koizumi T
Am J Hematol; 2004 Oct; 77(2):164-6. PubMed ID: 15389825
[TBL] [Abstract][Full Text] [Related]
52. Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA.
Ma W; Kantarjian H; Jilani I; Gorre M; Bhalla K; Ottmann O; Giles F; Albitar M
Leukemia; 2006 Nov; 20(11):1989-91. PubMed ID: 16932346
[TBL] [Abstract][Full Text] [Related]
53. [Ten years of molecular monitoring of chronic myeloid leukemia by quantitative RT-PCR].
Moravcová J; Brdicka R
Cas Lek Cesk; 2005; 144(1):32-7. PubMed ID: 15789779
[TBL] [Abstract][Full Text] [Related]
54. A pyrosequencing-based test for detection and relative quantification of the BCR-ABL1 T315I point mutation.
Schumacher JA; Szankasi P; Bahler DW; Ho AK; Kelley TW
J Clin Pathol; 2011 Jul; 64(7):618-25. PubMed ID: 21486895
[TBL] [Abstract][Full Text] [Related]
55. Analysis of BCR/ABL transcripts in chronic myeloid patients by nested PCR using an immunoassay-like detection format.
Barbu V; Alpha-Bazin B; Pepin D; Morand-Joubert L; Chypre C; Bereziat G
Mol Cell Probes; 1994 Jun; 8(3):251-6. PubMed ID: 7969201
[TBL] [Abstract][Full Text] [Related]
56. Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR.
Yamamoto M; Kakihana K; Ohashi K; Yamaguchi T; Tadokoro K; Akiyama H; Sakamaki H
Int J Hematol; 2009 May; 89(4):482-488. PubMed ID: 19343480
[TBL] [Abstract][Full Text] [Related]
57. Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy.
Cilloni D; Saglio G
Semin Hematol; 2003 Apr; 40(2 Suppl 2):37-41. PubMed ID: 12783374
[TBL] [Abstract][Full Text] [Related]
58. Harmonization of molecular monitoring of CML therapy in Europe.
Müller MC; Cross NC; Erben P; Schenk T; Hanfstein B; Ernst T; Hehlmann R; Branford S; Saglio G; Hochhaus A
Leukemia; 2009 Nov; 23(11):1957-63. PubMed ID: 19710700
[TBL] [Abstract][Full Text] [Related]
59. A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia.
Khorashad JS; Thelwell N; Milojkovic D; Marin D; Watson JA; Goldman JM; Apperley JF; Foroni L; Reid AG
J Clin Pathol; 2008 Jul; 61(7):863-5. PubMed ID: 18587017
[TBL] [Abstract][Full Text] [Related]
60. Rapid quantitative detection of the T315I mutation in patients with chronic myelogenous leukemia.
Yin L; Dittman D; Chenn A
Diagn Mol Pathol; 2012 Mar; 21(1):34-9. PubMed ID: 22306673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
